CAS 1445385-02-3

Lumicitabine

Description:

Lumicitabine, identified by its CAS number 1445385-02-3, is a novel nucleoside analog that has garnered attention in the field of antiviral research, particularly for its potential application in treating viral infections. As a chemical entity, it exhibits structural similarities to naturally occurring nucleosides, which allows it to interfere with viral replication processes. Lumicitabine is characterized by its ability to inhibit viral polymerases, thereby disrupting the synthesis of viral nucleic acids. This mechanism of action positions it as a promising candidate in the development of antiviral therapies. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its efficacy and safety profile in clinical settings. Research into Lumicitabine's therapeutic potential continues, with ongoing studies aimed at elucidating its effectiveness against various viral pathogens and understanding its interactions with other medications. As with any investigational drug, comprehensive clinical trials are essential to establish its therapeutic index and potential side effects.

Lumicitabine

CAS: 1445385-02-3

Lumicitabine (ALS-008176) is an inhibitor of RSV polymerase.

Formula: C₁₈H₂₅ClFN₃O₆

Color and Shape: Solid

Molecular weight: 433.86

Ref: TM-TQ0034

4'-C-(Chloromethyl)-2'-deoxy-2'-fluoro-cytidine 3',5'-Bis(2-methylpropanoate)

Controlled Product

CAS: 1445385-02-3

Formula: C₁₈H₂₅ClFN₃O₆

Color and Shape: Neat

Molecular weight: 433.86

Ref: TR-C371125

ALS-8176

CAS: 1445385-02-3

ALS-8176 is a benzimidazole compound that has been shown to be effective against both wild-type and syncytial viruses. It is also active against the hepatitis B virus, which causes fulminant hepatitis in humans and death in 30% of cases. The antiviral activity of ALS-8176 was demonstrated by its ability to inhibit viral DNA synthesis and to prevent the release of new viral particles. ALS-8176 has also been shown to have a broad spectrum of activity against paramyxoviruses, including mumps, measles, and respiratory syncytial virus (RSV). This drug can be used for the treatment of influenza A and B when administered during the early stages of infection. ALS-8176 blocks the antibody response to influenza virus infection as well as monoclonal antibody binding sites on the hemagglutinin protein, preventing fusion between infected cells.

Formula: C₁₈H₂₅ClFN₃O₆

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 433.86 g/mol

Ref: 3D-NA63420